CommercialBilling CodesHigh impact
New Claims Editing Rules To Be Implemented in December 2026
BCBS Illinois·IL · Ophthalmology, Endocrinology, Rheumatology·Reimbursement
Effective date
Dec 1, 2026
We identified it
Aug 22, 2026
Summary
Blue Cross Blue Shield of Illinois is implementing new claims editing rules effective December 1, 2026, that establish maximum unit limits for five specific injectable drugs and add drug wastage modifier validation. Claims exceeding these limits will be rejected with reason codes beginning with 'G.' Billing teams must update their systems to enforce these quantity restrictions and ensure proper wastage modifier application.
Action Required
By November 15, 2026: Billing team must update Lyric software database and claims editing rules to enforce the following unit limits: J0897 (Denosumab) limited to 60 units every 6 months with osteoporosis diagnosis; J0178 (Aflibercept) limited to 4 units every 4 weeks; J2778 (Ranibizumab) limited to 5 units every 4 weeks; J2502 (Pasireotide) limited to 60 units every 4 weeks with acromegaly diagnosis; Q5128 (Ranibizumab-eqrn) limited to 10 units every 4 weeks with wet AMD, RVO, or myopic CNV diagnosis. Implement validation rules to flag missing or incorrectly applied drug wastage modifiers (JW or JZ) on single-use vial claims. Update provider encounter forms and billing documentation to reflect new quantity limits and modifiers. Train billing and coding staff on the new editing rules. Test claims in sandbox environment before December 1, 2026. Failure to comply will result in claim rejections with 'G' reason codes and delayed reimbursement.